Frontiers in gastroenterology (Lausanne, Switzerland)最新文献

{"title":"Clinical study on the screening of biomarkers for Crohn's disease based on blood metabolomics.","authors":"Tongyuan Lin, Xianhong Hu, Kaifei Yuan, SiYuan Li, Ping Lin, Wei Wang, Li Cui, YuanYuan Wang, Ping Liu, Yong Yang","doi":"10.3389/fgstr.2026.1867424","DOIUrl":"10.3389/fgstr.2026.1867424","url":null,"abstract":"<p><strong>Background: </strong>Crohn's disease (CD) is a chronic inflammatory condition that affects the gastrointestinal tract. Currently, the diagnosis of CD is predominantly dependent on endoscopic procedures and histopathological tissue analysis. Endoscopy is an invasive procedure, patient compliance is poor, and the results are subject to the operator's subjective judgment. Infliximab (IFX) and ustekinumab (UST) are two new biologics used for the treatment of CD, which are effective in reducing inflammatory markers. However, the correlation between blood metabolites and inflammatory markers has rarely been studied in the biologic agents employed in the management of CD, and their effects on metabolic processes remain inadequately understood. This study aimed to elucidate the effects of IFX and UST on the blood metabolites in patients with CD, investigate the correlations between metabolic variations and clinical indicators, and examine the relationship between the identified biomarkers and clinical efficacy.</p><p><strong>Methods: </strong>A total of 81 patients with CD who were receiving biologic therapy enrolled at week 16 between January 2022 and December 2023 (45 receiving IFX and 36 receiving UST) and 45 healthy controls were included. Metabolite profiling was performed using high-performance liquid chromatography-tandem mass spectrometry, followed by multivariate statistical and pathway enrichment analyses to identify differential metabolites and their correlations with clinical indicators.</p><p><strong>Result: </strong>Despite achieving clinical remission, both the IFX and UST groups exhibited significantly elevated C-reactive protein levels and erythrocyte sedimentation rate values compared with the control group (<i>p</i> < 0.05). IFX primarily influenced amino acid metabolism, including pathways involving arginine and glutamine, and glycolysis and the tricarboxylic acid cycle. UST impacted glutathione and purine metabolism. Pearson's correlation analysis demonstrated that l-arginine, l-glutamine, and l-lysine were significantly negatively correlated with C-reactive protein. In the UST group, glutathione, adenosine, and hypoxanthine were primarily significantly negatively correlated with C-reactive protein and absolute lymphocyte count (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>We identified two sets of diagnostic biomarkers: the biomarkers for the IFX group were l-arginine, l-glutamine, and l-lysine, while those for the UST group were glutathione and adenosine.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1867424"},"PeriodicalIF":0.0,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13441770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148686861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent advances, comparative performance, and data requirements of artificial intelligence-assisted technologies for the diagnosis of gastric cancer.","authors":"Ziyang Zhang, Zhaorui Liu, Xin Zhang, Keke Lv, Yayu Huang, Chenxi Zheng, Tianlin He","doi":"10.3389/fgstr.2026.1878353","DOIUrl":"https://doi.org/10.3389/fgstr.2026.1878353","url":null,"abstract":"<p><p>Early diagnosis of gastric cancer is critical for improving prognosis and increasing the 5-year survival rate. However, gastroscopy and pathological examination are invasive, resource-dependent, and associated with low adherence, while conventional serological and imaging screening methods have limited sensitivity for early lesions. In recent years, artificial intelligence (AI), especially deep learning, has improved the efficiency and accuracy of real-time endoscopic detection, digital pathological recognition, non-contrast CT-based opportunistic screening, and multimodal diagnostic decision support. This review summarizes recent advances in AI-assisted technologies for gastric cancer diagnosis and, in response to the need for a clearer methodological and quantitative framework, compares representative models according to data modality, model architecture, dataset size, validation strategy, and reported diagnostic performance, including AUC, accuracy, sensitivity, specificity, precision/positive predictive value (PPV), and F1 score when available. We further discuss how data size, modality diversity, annotation granularity, class imbalance, and missing modalities influence model performance in real-world multicenter settings. Finally, we propose a structured multimodal AI-clinical decision support system (AI-CDSS) framework integrating CT imaging, endoscopic images and videos, whole-slide pathological images, serological indicators, molecular biomarkers, and clinical reports. Although AI-assisted diagnosis has shown considerable promise, clinical translation still requires prospective multicenter validation, standardized reporting of performance metrics, interpretable model outputs, privacy-preserving data governance, and regulatory-compliant deployment.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1878353"},"PeriodicalIF":0.0,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13469662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Advances in the treatment of acute severe ulcerative colitis.","authors":"Hirannya Karunadasa, Ronan O'Connor, Danny Con, Ashish Srinivasan, Abhinav Vasudevan","doi":"10.3389/fgstr.2026.1924886","DOIUrl":"10.3389/fgstr.2026.1924886","url":null,"abstract":"","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1924886"},"PeriodicalIF":0.0,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13437313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148681238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: The multifaceted role of cholangiocytes in neoplastic and non-neoplastic cholangiopathies: from bench to bedside.","authors":"Alessandro Gambella, Michele Pinon","doi":"10.3389/fgstr.2026.1874974","DOIUrl":"10.3389/fgstr.2026.1874974","url":null,"abstract":"","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1874974"},"PeriodicalIF":0.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13414132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited discriminative performance of endoscopic deep learning for <i>Helicobacter pylori</i> status assessment in gastric cancer patients: a retrospective study.","authors":"Wenyi Zhou, Yixing Wang, Yuhong Wang, Yongluo Jiang, Wencan He, Binbin Xu","doi":"10.3389/fgstr.2026.1878650","DOIUrl":"10.3389/fgstr.2026.1878650","url":null,"abstract":"<p><strong>Objectives: </strong><i>Helicobacter pylori</i> infection is a major risk factor for gastric cancer, but evidence for predicting <i>H. pylori</i> status from endoscopic images in patients with established gastric cancer remains limited. We evaluated the performance of endoscopic image-based classification models for <i>H. pylori</i> status in a retrospective gastric cancer cohort.</p><p><strong>Methods: </strong>We retrospectively collected 602 endoscopic images from 337 patients with gastric cancer treated at a tertiary cancer center. After preprocessing and quality control, 576 images from 329 patients were retained for model development and evaluation. <i>Helicobacter pylori</i> status was defined using routine clinical testing, including serum anti-<i>H. pylori</i> IgG and/or the ¹³C urea breath test. Endoscopic image classification models were evaluated across repeated stratified train, validation, and test splits. The primary performance metric was the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Model discrimination was limited. The best-performing approach achieved a median test AUC of 0.6255, with sensitivity of 0.7308, specificity of 0.3714, accuracy of 0.6092, and F1 score of 0.6800. Fine-tuning showed a higher median AUC than retraining, but discrimination remained limited in both strategies.</p><p><strong>Conclusions: </strong>In this retrospective gastric cancer cohort, endoscopic image-based classification showed limited ability to discriminate <i>H. pylori</i> status. These findings suggest that image-based assessment of <i>H. pylori</i> status in patients with gastric cancer remains challenging and may require more rigorous phenotyping, larger datasets, and validation across clinically diverse populations.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1878650"},"PeriodicalIF":0.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13414106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Helicobacter pylori</i> infection in gastric cancer patients in French Guiana: a hospital-based study (2018-2023).","authors":"Qiannan Wang, Kinan Drak Alsibai, Sarah Bailly, Jean-Pierre Droz, Dominique Louvel, Mathieu Nacher, Alolia Aboikoni","doi":"10.3389/fgstr.2026.1832175","DOIUrl":"10.3389/fgstr.2026.1832175","url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori</i> infection is a major etiological factor for gastric cancer, but its prognostic relevance once invasive gastric cancer has developed remains uncertain in French Guiana.</p><p><strong>Methods: </strong>We conducted a retrospective hospital-based study including all patients diagnosed with histologically confirmed invasive gastric carcinoma at Cayenne Hospital Center between 2018 and 2023. <i>H. pylori</i> status was assessed by routine histopathology. Sociodemographic, clinicopathological, and histological characteristics, including associated gastric lesions, were collected. Overall survival was estimated using the Kaplan-Meier method and compared using the log-rank test according to <i>H. pylori</i> status and initial management strategy. Exploratory multivariable Cox regression analyses were performed.</p><p><strong>Results: </strong>Eighty-two patients were included, of whom 43 (52.4%) were <i>H. pylori</i>-positive. <i>H. pylori</i> positivity was significantly associated with non-active chronic gastritis, whereas <i>H. pylori</i> detection was uncommon in active chronic gastritis. <i>H. pylori</i> status was not associated with tumor location, histological subtype, differentiation, or preneoplastic lesions. Median follow-up was 25.7 months. Overall survival did not differ between <i>H. pylori</i>-positive and <i>H. pylori</i>-negative patients. In multivariable analyses, <i>H. pylori</i> status was not associated with survival, whereas initial management was strongly associated with outcome, likely reflecting disease stage at diagnosis rather than a causal treatment effect.</p><p><strong>Conclusion: </strong>Routine histology detected <i>H. pylori</i> in about half of gastric tumors, with an association with non-active chronic gastritis. <i>H. pylori</i> status was not associated with survival; differences by initial management likely reflected disease severity, with interpretation limited by incomplete TNM staging.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1832175"},"PeriodicalIF":0.0,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13414184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy safety of linaclotide combined with polyethylene glycol for bowel preparation in patients with constipation: a meta-analysis.","authors":"Guoli Li, Hongfang Zhang, Lamei Li, Yun Huang","doi":"10.3389/fgstr.2026.1694950","DOIUrl":"10.3389/fgstr.2026.1694950","url":null,"abstract":"<p><strong>Background: </strong>In patients with chronic constipation, standard bowel preparation using polyethylene glycol (PEG) often results in inadequate intestinal cleansing, complicating colonoscopy. This study systematically assessed the efficacy and safety of linaclotide combined with PEG (linaclotide-PEG) compared to PEG alone.</p><p><strong>Methods: </strong>A systematic search was conducted in PubMed, EMBASE, Web of Science, CENTRAL, CNKI, VIP, and Wanfang databases up to February 1, 2025, to identify randomized controlled trials (RCTs) comparing linaclotide-PEG with PEG monotherapy in constipated patients. Study quality was assessed using the Cochrane Risk of Bias (RoB 2) tool. Data analyses were performed using Stata 16.0.</p><p><strong>Results: </strong>Eleven RCTs (2022-2024) involving 1,525 participants were included. Compared to PEG alone, linaclotide-PEG significantly improved overall bowel preparation quality [mean difference (MD)=0.82; 95% confidence interval (CI): 0.58-1.05; P < 0.05] and segment-specific cleansing scores (left colon: MD = 0.28; right colon: MD = 0.34; transverse colon: MD = 0.35; all P < 0.05). Additionally, polyp detection rate increased, procedural duration and cecal intubation times decreased, and patients' willingness to repeat colonoscopy improved significantly (all P < 0.05). The linaclotide-PEG regimen also reduced adverse reaction (nausea and vomiting events) (P < 0.05). No significant publication bias was detected (Egger's and Begg's tests: P > 0.05).</p><p><strong>Conclusion: </strong>Linaclotide-PEG is superior to PEG alone, enhancing bowel cleansing effectiveness, increasing lesion detection rates, shortening procedure times, and reducing adverse events, thus offering clear clinical advantages.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420250652929.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1694950"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13407309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EUS-guided transmural treatment of afferent loop syndrome: a systematic review and meta-analysis.","authors":"Thomas Balanis, Michael Doulberis, Radu Tutuian","doi":"10.3389/fgstr.2026.1853386","DOIUrl":"10.3389/fgstr.2026.1853386","url":null,"abstract":"<p><strong>Background: </strong>Afferent loop syndrome (ALS) is an uncommon but clinically relevant complication after pancreaticobiliary or upper gastrointestinal reconstruction, most often in patients with recurrent malignant disease. Endoscopic ultrasound-guided creation of a transmural bypass, either as gastroenterostomy or enteroenterostomy, has emerged as a minimally invasive alternative to surgery or percutaneous drainage. We aimed to systematically review the available evidence and provide a pooled descriptive analysis of the efficacy and safety of EUS-guided treatment for ALS.</p><p><strong>Methods: </strong>A systematic review was performed in accordance with PRISMA principles. PubMed/MEDLINE, Embase and the Cochrane Library were searched up to 15 May 2025 for studies reporting EUS-guided gastroenterostomy or enteroenterostomy for ALS. Case reports, case series and observational studies with extractable outcome data were eligible. Data on study design, indication, stent type, technical success, clinical success, adverse events and follow-up were extracted and synthesized.</p><p><strong>Results: </strong>Twelve studies involving 134 patients were included. On crude analysis, technical success was achieved in 132/134 patients (98.5%), clinical success in 127/134 (94.8%), and adverse events were reported in 13/134 (9.7%). In the pooled random-effects analysis, the technical success rate was 93.5% (95% CI 87.1-96.8; I²=0%), the clinical success rate was 91.0% (95% CI 84.5-94.9; I²=0%), and the overall adverse-event rate was 14.6% (95% CI 9.1-22.5; I²=0%). Adverse events were mainly procedure-related pain, fever, stent misdeployment, peritonitis or intra-abdominal infection. Electrocautery-enhanced lumen-apposing metal stents were used in most studies, whereas fully covered self-expandable metal stents were used in a smaller subset. Reported follow-up ranged from 1 to 15 months.</p><p><strong>Conclusions: </strong>EUS-guided transmural bypass represents a promising, minimally invasive, and technically feasible alternative for the management of ALS. However, given the retrospective nature and small sample sizes of the available evidence, larger comparative trials are warranted to define its definitive role.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1853386"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13407301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148610801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-endoscopy gastric cancer in Latin America: a multicentre cohort study from Colombia.","authors":"Hernando Marulanda-Fernandez, Juan Sebastián Frías Ordoñez, Gilberto Jaramillo Trujillo, Julián Parga Bermúdez, Jean Sebastián Barrero Gómez, Silvia Valentina Monsalve Rico, Elder Otero Ramos, Lina Otero Parra, William Otero-Regino","doi":"10.3389/fgstr.2026.1823329","DOIUrl":"10.3389/fgstr.2026.1823329","url":null,"abstract":"<p><strong>Background: </strong>Post-endoscopy gastric cancer (PEGC), defined as gastric cancer diagnosed after a negative upper gastrointestinal endoscopy, is considered a key indicator of endoscopic quality. Although international studies estimate that PEGC accounts for 5-11% of gastric cancer cases, evidence from Latin America remains scarce.</p><p><strong>Methods: </strong>We conducted a retrospective multicentre observational study across three tertiary hospitals in Bogotá, Colombia (2024-2025). Adult patients with histologically confirmed gastric neoplasms were included. PEGC was defined as cancer diagnosed between 6 and 36 months after a negative endoscopy. Clinical characteristics, tumour location, and hospital outcomes were compared between PEGC and non-PEGC cases.</p><p><strong>Results: </strong>Amongst 599 patients, 71 met criteria for PEGC, corresponding to a frequency of 11.9% (95% CI: 9.5-14.7). Helicobacter pylori positivity was 67.1% overall and 70.4% amongst PEGC cases. PEGC was associated with higher rates of palliative management (23.9% vs 2.8%; OR 10.77; 95% CI: 5.09-22.77; p<0.001) and increased in-hospital mortality (16.9% vs 7.0%; OR 2.70; 95% CI: 1.33-5.46; p=0.004).</p><p><strong>Conclusion: </strong>PEGC was frequent in this Colombian cohort and associated with adverse hospital outcomes, highlighting missed diagnostic opportunities and the need to strengthen endoscopic quality standards in high-burden regions. These findings support the incorporation of PEGC rate as a quality indicator for upper gastrointestinal endoscopy in high-incidence regions.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1823329"},"PeriodicalIF":0.0,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13388187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148563896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic pancreatitis: how does surgery step in?","authors":"Luca Santagiuliana, Federico Gronchi, Tommaso Dall'Olio, Gabriella Lionetto, Matteo De Pastena, Giuseppe Malleo, Salvatore Paiella, Roberto Salvia","doi":"10.3389/fgstr.2026.1861029","DOIUrl":"10.3389/fgstr.2026.1861029","url":null,"abstract":"<p><p>Chronic pancreatitis (CP) is a progressive inflammatory disorder of the pancreas characterized by irreversible morphological changes that lead to chronic abdominal pain, exocrine and endocrine insufficiency, and a significant reduction in quality of life. Historically, surgical intervention was considered a last-line option, reserved for patients in whom conservative or minimally invasive therapies had failed. However, growing evidence suggests that early surgical management may provide superior outcomes in terms of pain control and quality of life. The surgical management of CP encompasses a spectrum of procedures tailored to disease morphology and symptom profile. These include drainage procedures for patients with a dilated pancreatic duct, formal pancreatic resections for localized inflammatory masses or in cases with a high suspicion of malignancy, and combined resection-drainage techniques when ductal dilatation coexists with an inflammatory mass in the pancreatic head. A multidisciplinary evaluation is recommended for all patients prior to intervention to ensure optimal patient selection and individualized treatment planning. This review provides a narrative synthesis of the current literature on surgical indications, timing, techniques, postoperative outcomes, and long-term results, offering a comprehensive overview of contemporary evidence and clinical decision-making in the surgical management of CP.</p>","PeriodicalId":73085,"journal":{"name":"Frontiers in gastroenterology (Lausanne, Switzerland)","volume":"5 ","pages":"1861029"},"PeriodicalIF":0.0,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13388206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148563841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}